Jade Biosciences, Inc. (JBIO)Healthcare | Biotechnology | Waltham, United States | NasdaqCM
21.30 USD
+0.35
(1.671%)
⇧
(July 13, 2026, 4 p.m.
EDT)
After hours: 21.30 |
Hot Take ↕ | July 11, 2026, 7:06 a.m. EDT
The investment case here is fundamentally broken despite the company's recent capital raise and inclusion in growth indexes. The stock has suffered a catastrophic multi-year collapse, dropping nearly 98% from its peak, with the last two years showing double-digit declines. This is not a temporary correction; the market has permanently repriced the business quality, likely due to failed clinical trials or lack of commercial traction. The balance sheet, while currently debt-light, is bleeding cash with negative operating flows, and the negative earnings confirm the company is not generating value. The dividend paid recently is a red flag, representing a return of capital in a dying business rather than sustainable income. On the short end, the heavy put writing suggests traders are bracing for further weakness, making any bounce a potential trap. Avoid this security entirely. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.177661 |
| AutoETS | 0.184823 |
| AutoTheta | 0.387228 |
| AutoARIMA | 0.467291 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 32% |
| H-stat | 6.11 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.142 |
| Excess Kurtosis | -0.84 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Last Dividend Date | 2025-04-28 |
| Debt to Equity Ratio | 0.273 |
| Market Cap | 1,296,315,264 |
| Forward P/E | -9.34 |
| Website | https://jadebiosciences.com |
As of July 11, 2026, 7:06 a.m. EDT: Speculators are aggressively positioning for downside protection, evidenced by massive open interest in out-of-the-money puts (130 volume vs 80 OI at the nearest expiry) compared to negligible call activity. While there is some new call volume at the $17.50 strike, the overwhelming sentiment is hedging against a drop below current levels rather than betting on a rally.
| Date | Dividend | Yield % |
|---|---|---|
| 2025-04-29 | 2.4 | 23.668638 |
| Attribute | Value |
|---|---|
| 52 Week Change | 1.3277779 |
| Address1 | Building 23 |
| Address2 | Suite 105 221 Crescent Street |
| All Time High | 1,134.525 |
| All Time Low | 6.565 |
| Ask | 25.75 |
| Ask Size | 2 |
| Audit Risk | 7 |
| Average Daily Volume10 Day | 1,178,320 |
| Average Daily Volume3 Month | 1,018,145 |
| Average Volume | 1,018,145 |
| Average Volume10Days | 1,178,320 |
| Bid | 15.33 |
| Bid Size | 2 |
| Board Risk | 7 |
| Book Value | 6.008 |
| City | Waltham |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 10 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 21.3 |
| Current Ratio | 14.288 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 21.53 |
| Day Low | 19.94 |
| Debt To Equity | 0.273 |
| Display Name | Jade Biosciences |
| Dividend Date | 1,745,798,400 |
| Earnings Timestamp End | 1,778,788,800 |
| Earnings Timestamp Start | 1,778,788,800 |
| Ebitda Margins | 0.0 |
| Enterprise Value | 740,880,320 |
| Eps Current Year | -2.28165 |
| Eps Forward | -2.27984 |
| Eps Trailing Twelve Months | -2.67 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 21.0365 |
| Fifty Day Average Change | 0.2634983 |
| Fifty Day Average Change Percent | 0.012525767 |
| Fifty Two Week Change Percent | 132.77779 |
| Fifty Two Week High | 28.0 |
| Fifty Two Week High Change | -6.700001 |
| Fifty Two Week High Change Percent | -0.23928574 |
| Fifty Two Week Low | 6.67 |
| Fifty Two Week Low Change | 14.629999 |
| Fifty Two Week Low Change Percent | 2.1934032 |
| Fifty Two Week Range | 6.67 - 28.0 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,625,059,800,000 |
| Float Shares | 39,693,731 |
| Forward Eps | -2.27984 |
| Forward P E | -9.342761 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 55 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,782,864,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.0083 |
| Held Percent Institutions | 0.88188004 |
| Implied Shares Outstanding | 60,859,875 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Dividend Date | 1,745,884,800 |
| Last Dividend Value | 2.4 |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,745,884,800 |
| Last Split Factor | 1:35 |
| Long Business Summary | Jade Biosciences, Inc. operates as a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune diseases. It develops JADE101, a monoclonal antibody to block the A PRoliferation Inducing Ligand protein, which is in phase 1 clinical trial. The company also develops JADE201 and JADE-003, which are in preclinical development stage. Jade Biosciences, Inc. has a collaboration agreement with Paragon Therapeutics, Inc. Jade Biosciences, Inc. is based in Waltham, Massachusetts. |
| Long Name | Jade Biosciences, Inc. |
| Market | us_market |
| Market Cap | 1,296,315,264 |
| Market State | PREPRE |
| Max Age | 86,400 |
| Message Board Id | finmb_1889513328 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | -95,097,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 1,275,014,381 |
| Number Of Analyst Opinions | 8 |
| Open | 20.46 |
| Operating Cashflow | -100,013,000 |
| Operating Margins | 0.0 |
| Overall Risk | 9 |
| Payout Ratio | 0.0 |
| Phone | 781 312 3013 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 21.3 |
| Post Market Time | 1,783,982,483 |
| Previous Close | 20.95 |
| Price Eps Current Year | -9.335349 |
| Price Hint | 2 |
| Price To Book | 3.5452728 |
| Profit Margins | 0.0 |
| Quick Ratio | 13.964 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | 0.349998 |
| Regular Market Change Percent | 1.67064 |
| Regular Market Day High | 21.53 |
| Regular Market Day Low | 19.94 |
| Regular Market Day Range | 19.94 - 21.53 |
| Regular Market Open | 20.46 |
| Regular Market Previous Close | 20.95 |
| Regular Market Price | 21.3 |
| Regular Market Time | 1,783,972,800 |
| Regular Market Volume | 1,587,624 |
| Sand P52 Week Change | 0.20847368 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 60,859,875 |
| Shares Percent Shares Out | 0.1339 |
| Shares Short | 8,148,753 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 3,163,082 |
| Short Name | Jade Biosciences, Inc. |
| Short Percent Of Float | 0.16549999 |
| Short Ratio | 4.89 |
| Source Interval | 15 |
| State | MA |
| Symbol | JBIO |
| Target High Price | 74.0 |
| Target Low Price | 40.0 |
| Target Mean Price | 48.5 |
| Target Median Price | 45.0 |
| Total Cash | 311,295,008 |
| Total Cash Per Share | 6.307 |
| Total Debt | 808,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -2.67 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 15.6479 |
| Two Hundred Day Average Change | 5.6520996 |
| Two Hundred Day Average Change Percent | 0.361205 |
| Type Disp | Equity |
| Volume | 1,587,624 |
| Website | https://jadebiosciences.com |
| Zip | 2,453 |